.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Medtronic
Fuji
Boehringer Ingelheim
Queensland Health
QuintilesIMS
UBS
AstraZeneca
Farmers Insurance

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,070,808 protect, and when does it expire?


Patent ► Subscribe protects EMSAM and is included in one NDA.

This patent has three patent family members in two countries.

Summary for Patent: ► Subscribe

Title:Adhesive mixture for transdermal delivery of highly plasticizing drugs
Abstract:Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
Inventor(s): Govil; Sharad K. (Essex, VT), Weimann; Ludwig J. (Burlington, VT)
Assignee: Mylan Technologies, Inc. (St. Albans, VT)
Application Number:09/754,909
Patent Claim Types:
see list of patent claims
Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006RXYesYes► Subscribe► SubscribeYY
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-002Feb 27, 2006RXYesNo► Subscribe► SubscribeYY
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-003Feb 27, 2006RXYesNo► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,150,881Adhesive mixture for transdermal delivery of highly plasticizing drugs► Subscribe
8,846,093Adhesive mixture for transdermal delivery of highly plasticizing drugs► Subscribe
7,638,140Adhesive mixture for transdermal delivery of highly plasticizing drugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
JapanH1160475► Subscribe
European Patent Office1561461► Subscribe
European Patent Office0887075► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
US Army
Farmers Insurance
Cerilliant
Cantor Fitzgerald
Fuji
Accenture
Johnson and Johnson
Fish and Richardson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot